ProShares UltraShort Health Care
3 hedge funds and large institutions have $10.5K invested in ProShares UltraShort Health Care in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
592% more call options, than puts
Call options by funds: $192M | Put options by funds: $27.7M
261% more capital invested
Capital invested by funds: $2.9K → $10.5K (+$7.59K)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
50% more funds holding
Funds holding: 2 → 3 (+1)
0.17% more ownership
Funds ownership: 0.11% → 0.28% (+0.17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$7.64K |
| 2 |
CG
Cutler Group
San Francisco,
California
|
+$1.32K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$26 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$27 |
RXD Hedge Fund Activity: Q4 2023 in Review
3 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort Health Care (RXD) for Q4 2023, worth a combined $10.5K — up 261% from $2.9K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new RXD positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $7.64K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $27 sold.
- 3 institutional investors held ProShares UltraShort Health Care (RXD) as of Q4 2023, up from 2 in Q3 2023.
- Funds reported $10.5K of ProShares UltraShort Health Care stock for Q4 2023, up 261% quarter-over-quarter.
- 2 funds opened new ProShares UltraShort Health Care positions in Q4 2023 and 1 closed out, a net change of +1 holder.
- The largest ProShares UltraShort Health Care buyer in Q4 2023 was UBS Group, an estimated $7.64K added.
- The largest ProShares UltraShort Health Care seller in Q4 2023 was JP Morgan Chase, an estimated $27 sold.
Based on aggregated 13F filings for Q4 2023.